In a similar study, Rubnitz et al[18] reported the safety of KIR-mismatched NK cell infusion as post-remission consolidation therapy for children with AML, with no relapses reported in the 10 patients treated. The gene discussed is KIR3DL1; the disease is acute myeloid leukemia.